In conclusion, our results showed that EBV-miR-BART-22 plays an oncogenic role by driving the EMT and metastasis of NPC by targeting MOSPD2 and activating the Wnt/β-catenin pathway. This evidence concerns the gene MOSPD2 and nasopharyngeal carcinoma.